Cargando…
Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis
Myasthenia gravis (MG) is an autoimmune disease primarily mediated by acetylcholine receptor antibodies (AChR-Ab), cellular immune dependence, and complement system involvement. Since the AChR on the postsynaptic membrane is destroyed by an immune attack, sufficient endplate potential cannot be gene...
Autores principales: | Xiao, Hai, Wu, Ka, Liang, Xiaoliu, Li, Rong, Lai, Keng Po |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384962/ https://www.ncbi.nlm.nih.gov/pubmed/34456922 http://dx.doi.org/10.3389/fimmu.2021.715036 |
Ejemplares similares
-
Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis
por: Muppidi, Srikanth, et al.
Publicado: (2019) -
Eculizumab: A Review in Generalized Myasthenia Gravis
por: Dhillon, Sohita
Publicado: (2018) -
Eculizumab versus rituximab in generalised myasthenia gravis
por: Nelke, Christopher, et al.
Publicado: (2022) -
Correction to: Eculizumab: A Review in Generalized Myasthenia Gravis
por: Dhillon, Sohita
Publicado: (2018) -
Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)